PROVENANCE

Provenance Bio Set to Further the Cell-Based Meat, Leather Alternatives, and Therapeutics Industries with Advanced Collagen Production

San Francisco, CA

For Immediate Release

Provenance Bio, LLC, a San Francisco-based startup working on leading edge complex protein production, announced today the successful creation of a specialized form of collagen to further the next generation of cultivated meats, leather alternatives, and next generation therapeutics built without animal inputs.

Collagen is the most abundant protein in animals. Provenance has produced full-length, type 1 collagen. Collagen type 1 has a predominately structural role in tissues and a recombinant form of it could lend structure in the building of a new crop of products derived from cellular agriculture.

Collagen in this form can give cultivated meats their structure, bioleather its standalone integrity, bioinks their support and shape fidelity in building 4D-printed products like organs for transplantation, and more.

Recombinant, full-length collagen formed into scaffolding for cultivated meats and transplantable organs is ideal as cells have evolved to recognize and attach to collagen, as the major component of natural extracellular matrix, giving properties to these products as found in nature.

Leather in its final form is predominantly type 1 collagen, and having this fundamental building block allows Provenance, alongside a partner, to unlock a new biosynthetic leather market by programming collagen into designed materials.

"We look forward to working with our partners to develop collagen according to their specifications that assist them in bringing completely new, supreme quality products to market," says Michalyn Andrews, CEO of Provenance Bio.

"Full-length collagen with specific modifications for functionality have, to-date, proven industrially difficult to procure in an animal-free system, so we are excited to have passed this hurdle and empower partners with highest quality and affordable collagen," says Andrews.

Cellular agriculture products will meet consumer demand for non-animal based replacements to goods these consumers have come to rely on while offering the same attributes they have come to expect. Provenance's unique collagen and production efficiency will speed these products to market, meeting a growing population's increasing demands, while offering a significantly lighter industrial footprint.

--

Provenance Bio is at the leading edge of complex protein production, facilitating the future of cultivated meats, leather alternatives, and next generation therapeutics. The company has developed new synthetic biology tools, harnessing their revolutionary protein production platform toward making previously out-of-reach proteins at scale - quality, cost, and environmentally-advantaged over traditional protein production means.

The company is managed by CEO and Co-Founder, Michalyn Andrews; Co-Founder, Dr. Zev Gartner; CBDO and Co-Founder, Christian Ewton; and, CTO, Dr. Aravind Somanchi.